Oncologist

期刊全称

Oncologist

期刊缩写

ONCOLOGIST

涉及主题

医学生物内科学遗传学癌症病理肿瘤科外科化学化疗生物化学生物信息学免疫学数学心理学

期刊介绍

The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.

期刊ISSN

print: 1083-7159

历年影响因子

2024年	2023年	2022年	2021年	2020年	2019年	2018年	2017年
4.8	5.8	5.837	0	5.025	5.252	5.306	4.962

历年发表/被引量

年份	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
发表量	240	417	378	336	349	450	430	326	298	224	273	233	268	252
被引量	9769	20947	22732	23528	23451	21533	16930	15002	14748	13717	13068	12730	11942	10800

h-Index

145

自引率

4.20%

涉及的研究领域

医学-肿瘤学

中科院2025年分区

大类	小类	TOP期刊	综述期刊
2区	2区肿瘤学	否	否

WOS期刊分区

JCR学科分类

JCR分区学科名称	收录数据库	JCR分区	分区排名
ONCOLOGY	SCIE	Q2	89/326

JCI学科分类

JCI分区学科名称	收录数据库	JCI分区	分区排名
ONCOLOGY	SCIE	Q2	88/326

期刊主页

http://theoncologist.alphamedpress.org/https://onlinelibrary.wiley.com/journal/1549490x

投稿网址

https://www.editorialmanager.com/TO

出版商

AlphaMed Press

出版国家（地区）

UNITED STATES

出版语言

English

出版周期

Monthly

每年出版文章数

278

Gold OA文章占比

79.47%

原创研究文献占比
(排除综述)

86.28%

SCI收录类型

Science Citation Index Expanded (SCIE)

Scopus (CiteScore)

PubMed链接

http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1083-7159%5BISSN%5D

平均审稿周期

一般,3-8周

平均录用比例

较难

Oncologist

JCR学科分类

JCI学科分类

期刊相关文献 (4828)

Landscape of T-cell engagers in solid tumors

实体瘤中T细胞衔接器的研究概况

Financial toxicity among patients with breast cancer: a systematic review and meta-analysis

乳腺癌患者的经济负担：系统评价和荟萃分析

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection

转移性胰腺癌吉西他滨联合白蛋白紫杉醇治疗后的二线化疗：疗效比较及人工智能指导的治疗选择

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

贝伐珠单抗联合替西罗莫司治疗晚期恶性肿瘤的I期研究：安全性、疗效及卵巢癌扩展研究

Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy

对于初始无法切除且伴有门静脉癌栓的肝细胞癌患者，在成功进行转化治疗后，辅助靶向免疫治疗的最佳持续时间

Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics

膀胱癌多维液体活检：循环肿瘤细胞、循环肿瘤DNA、外泌体和代谢组学的研究进展

Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects

多学科团队对分化良好型甲状腺癌的诊断和治疗：现状与展望

Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

基于疾病体积的转移性激素敏感性前列腺癌最佳治疗方案：系统评价和网络荟萃分析

Induction chemoimmunotherapy followed by concurrent radiotherapy in patients with locally advanced esophageal cancer: a single-arm phase 2 trial

局部晚期食管癌患者接受诱导化疗免疫治疗后同步放疗：一项单臂 II 期试验

Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial

格拉司琼透皮给药系统与帕洛诺司琼预防迟发性恶心呕吐的疗效比较：一项 III 期随机试验